Ovarian carcinoma: Care and survival in a community-based population

被引:10
作者
Yawn, BP
Wollan, P
Klee, M
Barrette, B
机构
[1] Olmsted Med Ctr, Dept Res, Rochester, MN 55904 USA
[2] Mayo Clin, Dept Obstet & Gynecol, Rochester, MN USA
关键词
ovarian cancer; cost of care; community population;
D O I
10.1016/S0149-2918(01)80037-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Previous studies of the management and costs of ovarian cancer have been based on data from oncology practices. Such studies may exclude patients who are not candidates for treatment and may not account for costs incurred during diagnosis or primary treatment. Objective: The purpose of this study was to describe the epidemiology, management, and costs of care of ovarian cancer in a geographically defined population to better rt fleet the total spectrum of the disease and its: care. Methods: We conducted a retrospective review of the medical records of all residents of Olmsted County, Minnesota, who received a first diagnosis of epithelial ovarian carcinoma (including postmortem diagnoses) between 1985 and 1997, Results: Of the 107 women with a new diagnosis of ovarian carcinoma, 42 (39%) had stage I or II tumors at the time of diagnosis. The mean age of the patients at the time of diagnosis was 64.7 years, and 20% were nulliparous. The diagnostic assessment for ovarian carcinoma was initiated by a family physician or internist in 50% of cases and by an obstetrician or gynecologist in 16% of cases. One hundred two patients (95%) underwent surgical treatment, and 80 (75%) received primary chemotherapy. The 5-year survival rate was 88% in those with stage I or II tumors and 17% in those with stage III or IV tumors. The mean charges for secondary care were higher than those for primary care ($36,110 vs $32,367; P < 0.05) in those receiving both types of therapy. Fifty percent of those dying of ovarian cancer received hospice care for a mean of 39.0 days before death. Conclusions: Most assessments leading to a diagnosis of ovarian carcinoma were initiated by primary carl physicians. In this community-based population, early-stage and low-grade turners were common (<greater than or equal to>30%) and were associated with lower costs of care and higher 5-year survival rates. Total treatment costs for those requiring secondary therapy were approximately twice the costs for those requiring primary treatment only, with similar to 50% of costs associated with inpatient care.
引用
收藏
页码:146 / 159
页数:14
相关论文
共 43 条
[1]  
*AM CANC SOC, 1996, EX SUMM OV CANC SCRE
[2]   OVARIAN-CANCER [J].
BARBER, HRK .
CA-A CANCER JOURNAL FOR CLINICIANS, 1986, 36 (03) :149-184
[3]   The epidemiology of ovarian cancer: A population-based study in Olmsted County, Minnesota, 1935-1991 [J].
Beard, CM ;
Hartmann, LC ;
Atkinson, EJ ;
O'Brien, PC ;
Malkasian, GD ;
Keeney, GL ;
Melton, LJ .
ANNALS OF EPIDEMIOLOGY, 2000, 10 (01) :14-23
[4]   Comparing cost-effectiveness analyses for the clinical oncology setting: The example of the Gynecologic Oncology Group 111 trial [J].
Bennett, CL ;
Stinson, TJ .
CANCER INVESTIGATION, 2000, 18 (03) :261-268
[5]   Topotecan for the treatment of advanced epithelial ovarian cancer:: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel [J].
Bookman, MA ;
Malmström, H ;
Bolis, G ;
Gordon, A ;
Lissoni, A ;
Krebs, JB ;
Fields, SZ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3345-3352
[6]   CHEMOPROPHYLAXIS WITH ORAL CIPROFLOXACIN IN OVARIAN-CANCER PATIENTS RECEIVING TAXOL [J].
CARLSON, JW ;
FOWLER, JM ;
SALTZMAN, AK ;
CARTER, JR ;
CHEN, MD ;
MITCHELL, SK ;
DUNN, D ;
CARSON, LF ;
ADCOCK, LL ;
TWIGGS, LB .
GYNECOLOGIC ONCOLOGY, 1994, 55 (03) :415-420
[7]   Re: "Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies" [J].
Clarke, M ;
Stewart, L .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1998, 148 (01) :102-103
[8]   Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study [J].
Creemers, GJ ;
Bolis, G ;
Gore, M ;
Scarfone, G ;
Lacave, AJ ;
Guastalla, JP ;
Despax, R ;
Favalli, G ;
Kreinberg, R ;
VanBelle, S ;
Hudson, I ;
Verweij, J ;
Huinink, WWT .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) :3056-3061
[9]  
Daly M, 1998, SEMIN ONCOL, V25, P255
[10]   Transvaginal sonography as a screening method for the detection of early ovarian cancer [J].
DePriest, PD ;
Gallion, HH ;
Pavlik, EJ ;
Kryscio, RJ ;
vanNagell, JR .
GYNECOLOGIC ONCOLOGY, 1997, 65 (03) :408-414